BofA warns Fed risks policy mistake with early rate cuts
Investing.com - H.C. Wainwright initiated coverage on Achieve Life Sciences (NASDAQ:ACHV) Thursday with a Buy rating and a $12.00 price target, citing the potential of the company’s nicotine addiction treatment. Currently trading at $2.58 with a market cap of $131.6 million, InvestingPro data shows the stock is trading slightly above its Fair Value.
The research firm highlighted cytisinicline, Achieve’s lead oral tablet asset, as having potential to address significant unmet needs in smoking cessation through what it describes as a differentiated efficacy and tolerability profile compared to existing treatments. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 6.64 and holds more cash than debt on its balance sheet.
With Achieve’s New Drug Application (NDA) now submitted to the FDA, H.C. Wainwright identified the next 12-18 months as a potential value inflection period for the stock, with possible FDA approval and commercial launch in 2026.
The firm specifically noted cytisinicline’s tolerability advantages over Chantix/generic varenicline as a key differentiator, stating that adverse events have been a limiting factor for varenicline adoption among physicians and patients.
H.C. Wainwright suggested that Achieve’s current enterprise value of $122 million undervalues both the strength of the data supporting the NDA and the size of the addressable market, where it projects peak cytisinicline sales could reach multiples of the company’s current valuation.
In other recent news, Achieve Life Sciences Inc. announced its Q2 2025 earnings, which met analysts’ expectations. The company reported an earnings per share (EPS) of -0.37, aligning with the forecasted figures. Achieve Life Sciences continues to focus on its strategic initiatives, particularly the development of cytisinicline for treating nicotine dependence. These developments indicate the company’s ongoing commitment to its core projects. There has been no mention of any mergers or acquisitions in the recent updates. Additionally, there were no analyst upgrades or downgrades reported for the company at this time. Investors and stakeholders are likely observing these developments closely as the company progresses with its initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.